Clinical Trial Update: Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE) [Phase 3]

View source ↗

Summary

Phase 3 trial update on alirocumab (ODYSSEY APPRISE) evaluating safety, tolerability, and effect in high cardiovascular risk patients with severe hypercholester…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2020-03-30